Squibb Company (NYSE:BMY) today announced results from CheckMate
-063, a Phase 2 single-arm, open-label study of Opdivo (nivolumab),
an investigational PD-1 immune checkpoint inhibitor, administered as a
single agent in patients with advanced squamous cell non-small cell lung
cancer (NSCLC) who have progressed after at least two prior systemic
treatments with 65% receiving three or more prior therapies (n=117).
With approximately 11 months of minimum follow up, the objective
response rate (ORR, the study’s primary endpoint) was 15% (95% CI = 8.7,
22.2) as assessed by an independent review committee (IRC) using RECIST
1.1 criteria and the median duration of response was not reached.
for Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology investment picks